Inclusion Criteria:  Females and males ≥ 18 years of age. Clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed. Use of insulin pump therapy for at least 3 months. Effective birth-control use in individuals of childbearing potential. Individuals of child-bearing potential must agree to use a highly effective method of birth control.  Exclusion Criteria:  Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2I (sodium-glucose transporter), GLP-1(glucagon-like peptide), Metformin, etc.). Current use of glucocorticoid medication (except low, stable does and inhaled steroids). Individuals with confirmed gastroparesis. Use of medication that alters gastrointestinal motility. Planned or ongoing pregnancy. Breastfeeding individuals. Severe hypoglycemia requiring hospitalization in the past three months. Severe diabetic ketoacidosis episode in the past three months. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator. Recent (< 6 months) acute macrovascular event e.g., acute coronary syndrome or cardiac surgery. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.